Sandoz announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved… read more.
The European Medicines Agency (EMA) has recommended 14 new medicines for approval at its September meeting. The key Committee on Human Medicinal Products (CHMP) reviews safety and efficacy… read more.
Alvotech and Advanz Pharma announced that the European Commission has approved Mynzepli as a biosimilar to Eylea (aflibercept), in a pre-filled syringe and vial. The centralized marketing authorization… read more.
Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung… read more.
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
Rheumatology specialist pharmacist Kalveer Flora started her work in rheumatology when the first biosimilar for rheumatology was launched in 2017. At that time, biosimilars were relatively new, and… read more.
April was a bumper month for drug approvals in Europe, with sixteen new products recommended by the European Medicines Agency’s (EMA) key committee on human medicines. This almost… read more.
Teva Pharmaceutical Industries Ltd. , and Samsung Bioepis Co., Ltd. announced the availability of Epysqli (eculizumab-aagh) in the U.S. Epysqli is a biosimilar to Soliris (eculizumab) for the… read more.
The European Medicines Agency rounded off a busy year by approving seventeen new medicines. At its December meeting, the Committee for Medicinal Products for Human Use (CHMP) also… read more.
Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission (EC) has granted marketing authorization for Wyost (C) and Jubbonti (denosumab), the first and… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Jubbonti, intended for the… read more.
Sandoz, a global leader in generic and biosimilar medicines, announced that the FDA has approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
